↓ Skip to main content

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Overview of attention for article published in Lancet Oncology, January 2019
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Citations

dimensions_citation
353 Dimensions

Readers on

mendeley
238 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Published in
Lancet Oncology, January 2019
DOI 10.1016/s1470-2045(18)30765-4
Pubmed ID
Authors

Arnaud Scherpereel, Julien Mazieres, Laurent Greillier, Sylvie Lantuejoul, Pascal Dô, Olivier Bylicki, Isabelle Monnet, Romain Corre, Clarisse Audigier-Valette, Myriam Locatelli-Sanchez, Olivier Molinier, Florian Guisier, Thierry Urban, Catherine Ligeza-Poisson, David Planchard, Elodie Amour, Franck Morin, Denis Moro-Sibilot, Gérard Zalcman, French Cooperative Thoracic Intergroup, Didier DEBIEUVRE, Sandrine HIRET, Jacques CADRANEL, Séverine FRABOULET-MOREAU, Delphine CARMIER

X Demographics

X Demographics

The data shown below were collected from the profiles of 107 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 238 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 238 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 30 13%
Other 28 12%
Student > Ph. D. Student 25 11%
Student > Master 19 8%
Student > Bachelor 19 8%
Other 38 16%
Unknown 79 33%
Readers by discipline Count As %
Medicine and Dentistry 84 35%
Biochemistry, Genetics and Molecular Biology 15 6%
Pharmacology, Toxicology and Pharmaceutical Science 13 5%
Nursing and Health Professions 11 5%
Immunology and Microbiology 6 3%
Other 23 10%
Unknown 86 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 82. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 May 2022.
All research outputs
#522,221
of 25,461,852 outputs
Outputs from Lancet Oncology
#661
of 6,901 outputs
Outputs of similar age
#11,925
of 447,696 outputs
Outputs of similar age from Lancet Oncology
#18
of 131 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,901 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.2. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 447,696 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 131 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.